NVS-32b

N/A

Report date: 2025/01/26 16:38:45

Base Information

Drug NameNVS-32b

Drug Alias NameNVS-32b2Dual CD32b Checkpoint Inhibitor/CD16a Activator (Novartis Institutes for Biomedical Research)Dual FcgRIIb Checkpoint Inhibitor/FcgRIIIa Activator (Novartis Institutes for Biomedical Research)NVS-32b1afucosylated anti-CD32b mAbs (Novartis Institutes for Biomedical Research)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor II-b antagonistsLow affinity immunoglobulin gamma Fc region receptor III-A agonists

TargetsLow affinity immunoglobulin gamma Fc region receptor II-bLow affinity immunoglobulin gamma Fc region receptor III-A

Therapy Area/IndicationsMultiple MyelomaLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNovartis Institutes For Biomedical Research Inc

China Registration ClassN/A

Develop Information

Active CompaniesNovartis Institutes For Biomedical Research Inc

Inactive CompaniesN/A

Active IndicationsMultiple MyelomaLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A